Related Experiment Video
Updated: May 3, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.0K
Putting the value into biosimilar decision making: the judgment value criteria.
Mirhelen Mendes de Abreu1, Vibeke Strand2, Roger Abramino Levy3
1Department of Medicine, Universidade Federal de São Carlos.
Autoimmunity Reviews
|January 21, 2014
Summary
Navigating biosimilar utilization requires clarifying challenges for policymakers, doctors, and patients. Understanding molecular comparability is key to assessing clinical relevance and informing decisions on biosimilar reuse.
Area of Science:
- Pharmacoeconomics
- Biopharmaceutical Science
- Health Policy
Background:
- Biosimilar medicines present unique challenges for healthcare stakeholders due to remaining uncertainties.
- Limited scientific understanding complicates decision-making processes regarding biosimilar adoption and patient care.
- The value chain for biosimilars hinges on demonstrating molecular comparability and its clinical implications.
Purpose of the Study:
- To clarify challenges faced by policymakers, clinicians, and patients in the context of biosimilar utilization.
- To present a knowledge-value chain framework for understanding biosimilar decision-making.
- To critically assess the molecular comparability of biosimilars and its impact on clinical outcomes.
Main Methods:
- Conceptual analysis of the biosimilar knowledge-value chain.
- Discussion of dimensions assigning value in the decision-making process for biosimilar reuse.
- Examination of molecular comparability metrics and their clinical relevance.
Main Results:
- Uncertainties surrounding biosimilars necessitate a structured approach to decision-making.
- A knowledge-value chain can illuminate the factors influencing biosimilar adoption.
- Molecular similarity assessment is crucial for evaluating potential clinical differences.
Conclusions:
- Clearer understanding and frameworks are needed to address biosimilar uncertainties.
- Policymakers must prioritize patient needs and scientific evidence in health policy decisions.
- Evaluating molecular comparability is essential for informed clinical utilization of biosimilars.
Related Concept Videos
01:09Decision Making: P-value Method
5.8K
The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can...
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can...
5.8K
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:26Pharmacokinetic Models: Comparison and Selection Criterion
490
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
490
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
01:13Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430